Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats: Lack of tolerance after chronic caffeine intake

Neuropsychopharmacology

Volumn 22, Issue 5, 2000, Pages 522-529

  Popoli, Patrizia ^a   Reggio, Rosaria ^a   Pèzzola, Antonella ^a  

^a Pharmacology Department   (Italy)

Author keywords

Adenosine A(2A) receptors; Chronic caffeine treatment; Dopamine D1 and D2 receptors; Parkinson's disease

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CAFFEINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; OXIDOPAMINE; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERANCE; MALE; MOTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BEHAVIOR, ANIMAL; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PYRIMIDINES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TIME FACTORS; TRIAZOLES;

EID: 0034017543     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00144-X     Document Type: Article

References (39)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Alexander G.R., Crutcher M.D. Functional architecture and basal ganglia circuits. neural substrates of parallel processing Trends Neurosci. 13:1990;266-271.
3. 2a purine receptors regulate striatal acetylcholine release. J Neurochem. 55:1990;31-37.
4. 2A receptor modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells. Eur J Pharmacol. 316:1996;325-331.
5. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 321:1997;143-147.
6. Ferré S., Herrera-Marschitz M., Grabowska-Andén M., Casa M., Ungerstedt U., Andén N.E. Postsynaptic dopamine/adenosine interaction. I. Adenosine analogues inhibit dopamine D. 2-mediated(behaviour in short-term reserpinized mice. Eur J Pharmacol 192):1991;25-29. a.
7. Ferré S., Von Euler G., Johansson B., Fredholm B., Fuxe K. Stimulation of high affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 88:1991;7238-7241. b.
8. 2 receptors in the neostriatum. Brain Res. 594:1992;124-130.
9. Ferré S., Fuxe K., Von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512.
10. Ferré S., O'Connor W.T., Fuxe K., Ungerstedt U. The striopallidal neuron. a main locus for adenosine-dopamine interactions in the brain J Neurosci. 13:1993;5402-5406.
11. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
12. 2 receptors in the rat striatum. Neuropharmacol. 38:1999;129-140.
13. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A., Adler D.M., Reppert S.M. Molecular cloning of the rat A2 adenosine receptors. selective co-expression with D2 dopamine receptors in rat striatum Mol Brain Res. 14:1992;186-195.
14. 2 receptor agonists but not to their synergistic interaction. Eur J Pharmacol. 262:1994;65-75.
15. Garrett B.E., Holtzman S.G. Does adenosine receptor blockade mediate caffeine-induced rotational behaviour? J Pharmacol Exp Ther. 274:1995;207-214. a.
16. Garrett B.E., Holtzman S.G. The effects of dopamine agonists on rotational behavior in non-tolerant and caffeine-tolerant rats. Behav Pharmacol. 6:1995;843-851. b.
17. Gerfen C.R., Engber T.M., Mahan L., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of strionigral and striopallidal neurons. Science. 250:1990;1429-1432.
18. Holtzman S.G., Mante S., Minneman K.P. Role of adenosine receptors in caffeine tolerance. J Pharmacol Exp Ther. 256:1991;62-68.
19. 2A antagonist. a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann Neurol. 43:1998;507-513.
20. Jacobson K.A., Von Lubitz D.K.J.E., Daly J.W., Fredholm B.B. Adenosine receptor ligands. diferences with acute versus chronic treatment Trends Pharmacol Sci. 17:1996;108-113.
21. 2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J Pharmacol Exp Ther. 267:1993;801-808.
22. 2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 251:1994;21-25.
23. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
24. Nikodijevic O., Jacobson K.A., Daly J.W. Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav. 44:1993;199-216. a.
25. Nikodijevic O., Jacobson K.A., Daly J.W. Effects of combinations of methylxanthines and adenosine analogs on locomotor activity in control and chronic caffeine-treated mice. Drug Dev Res. 30:1993;104-110. b.
26. 2A receptors. Trends Pharmacol Sci. 17:1996;364-372.
27. 1 agonists in dopamine-denervated rats. Eur J Neurosci. 8:1996;1176-1181.
28. Pollack A.E., Fink J.S. Adenosine antagonists potentiate D2-dopamine-dependent activation of Fos in the striopallidal pathway. Neuroscience. 68:1995;721-728.
29. 1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res. 743:1996;124-130.
30. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol. 287:1995;215-217.
31. 2 receptor antagonists stimulate motor activity. evidence for an increased effectiveness in aged rats Neurosci Lett. 251:1998;201-204.
32. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci. 18:1998;338-344.
33. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons. an in situ hybridization histochemistry study J Neurochem. 57:1991;1062-1067.
34. Schwarting P.K.W., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Progr Neurobiol. 50:1996;275-331.
35. Svenningsson P., Fredholm B.B. Caffeine mimics the effect of a dopamine D2/3 receptor agonist on the expression of immediate early genes in globus pallidus. Neuropharmacol. 36:1997;1309-1317.
36. 2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience. 80:1997;1171-1185. a.
37. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience. 79:1997;753-764. b.
38. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system in the rat brain. Acta Physiol Scand. 82( Suppl. 367):1971;69-93.
39. 2a adenosine receptor antagonist. J Pharmacol Exp Ther. 276:1996;398-404.